Emergent Biosolutions EBITDA 2010-2023 | EBS
Emergent Biosolutions ebitda from 2010 to 2023. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Emergent Biosolutions Annual EBITDA
(Millions of US $) |
| 2022 |
$-25 |
| 2021 |
$481 |
| 2020 |
$552 |
| 2019 |
$228 |
| 2018 |
$153 |
| 2017 |
$169 |
| 2016 |
$144 |
| 2015 |
$177 |
| 2014 |
$122 |
| 2013 |
$62 |
| 2012 |
$41 |
| 2011 |
$41 |
| 2010 |
$80 |
| 2009 |
$45 |
Emergent Biosolutions Quarterly EBITDA
(Millions of US $) |
| 2023-03-31 |
$-113 |
| 2022-12-31 |
$-29 |
| 2022-09-30 |
$-9 |
| 2022-06-30 |
$-27 |
| 2022-03-31 |
$38 |
| 2021-12-31 |
$308 |
| 2021-09-30 |
$-1 |
| 2021-06-30 |
$49 |
| 2021-03-31 |
$125 |
| 2020-12-31 |
$288 |
| 2020-09-30 |
$91 |
| 2020-06-30 |
$155 |
| 2020-03-31 |
$17 |
| 2019-12-31 |
$106 |
| 2019-09-30 |
$99 |
| 2019-06-30 |
$22 |
| 2019-03-31 |
$0 |
| 2018-12-31 |
$37 |
| 2018-09-30 |
$34 |
| 2018-06-30 |
$79 |
| 2018-03-31 |
$3 |
| 2017-12-31 |
$67 |
| 2017-09-30 |
$58 |
| 2017-06-30 |
$18 |
| 2017-03-31 |
$25 |
| 2016-12-31 |
$61 |
| 2016-09-30 |
$46 |
| 2016-06-30 |
$7 |
| 2016-03-31 |
$30 |
| 2015-12-31 |
$95 |
| 2015-09-30 |
$72 |
| 2015-06-30 |
$30 |
| 2015-03-31 |
$-20 |
| 2014-12-31 |
$84 |
| 2014-09-30 |
$40 |
| 2014-06-30 |
$16 |
| 2014-03-31 |
$-19 |
| 2013-12-31 |
$29 |
| 2013-09-30 |
$23 |
| 2013-06-30 |
$19 |
| 2013-03-31 |
$-9 |
| 2012-12-31 |
$28 |
| 2012-09-30 |
$13 |
| 2012-06-30 |
$11 |
| 2012-03-31 |
$-10 |
| 2011-12-31 |
$48 |
| 2011-09-30 |
$4 |
| 2011-06-30 |
$22 |
| 2011-03-31 |
$-33 |
| 2010-12-31 |
$37 |
| 2010-09-30 |
$22 |
| 2010-06-30 |
$16 |
| 2010-03-31 |
$4 |
| 2009-12-31 |
$5 |
| 2009-09-30 |
$-3 |
| 2009-06-30 |
$24 |
| 2009-03-31 |
$19 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.416B |
$1.121B |
|
Emergent BioSolutions, Inc. is a global specialty biopharmaceutical company offering specialized products to health care providers and governments to combat emerging public health threats. It also supplies vaccines to domestic and international non-government organizations and governments in/ outside of the U.S. BioThrax is the company's key Biodefense product, used for anthrax disease. The U.S. government is the primary purchaser of the company's Biodefense products. It supplies adjuvanted anthrax vaccine candidate, AV7909, to the U.S. government. It supplies smallpox vaccine ACAM2000, botulism therapeutic BAT, anthrax therapeutics 'raxibacumab & Anthrasil' and 3 other products to governments of different countries. It also retails 3 products Narcan nasal spray, Vaxchora and Vivoti. It provides contract development and manufacturing services to multiple pharma and biotech companies. The company has added key products Narcan nasal spray, ACAM2000, raxibacumab, Vaxchora and Vivoti through several acquisitions.
|
